MedTrace Logo

Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma

NCT00305149 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2006-03-21

No results posted yet for this study

Summary

.This study is trying to address change of chemotherapy dosage according to individual patient response to initial cycles of chemotherapy in order to reduce cumulative dose of chemotherapy.The study includes patients with early unfavorable and advanced hodgkin lymphoma. Patients with low risk were started with standard beacopp and only high risk patients were started with escalated beacopp.Following 2 cycles of therapy the patients were reassessed.Based on scintigraphy results decision was made regarding further therapylative chemotherapy for early responders and maximize dose intensity for late responders.

Conditions

  • Classical Hodgkin Lymphoma
  • Nodular Sclerosis
  • Mixed Cellularity
  • Lymphocyte Depletion
  • Lymphocyte Rich

Interventions

PROCEDURE

interim therapy scintigraphy study gallium scan or PET/CT

PROCEDURE

"interim gallium or PET/CT"

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Ron Epelbaum, ND · Rambam health care center, Bruce Rappaport Faculty of Medicine Technion

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2005-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305149 on ClinicalTrials.gov